SCYNEXIS Inc

135A

Company Profile

  • Business description

    SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

  • Contact

    1 Evertrust Plaza
    13th Floor
    Jersey CityNJ07302 - 6548
    USA

    T: +1 201 884-5485

    E: [email protected]

    https://www.scynexis.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    29

Stocks News & Analysis

stocks

Are small caps finally back?

Does renewed investor interest point to a structural shift in the underperforming factor?
stocks

Chart of the Week: Modest earnings growth at odds with overvalued bank shares

The latest update from our Industry Pulse report.
stocks

Solid start to fiscal 2026 for BHP

Production guidance is maintained by management.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,329.1050.900.55%
CAC 408,225.7818.910.23%
DAX 4024,207.7956.660.23%
Dow JONES (US)46,734.61144.200.31%
FTSE 1009,578.5763.570.67%
HKSE25,967.98186.210.72%
NASDAQ22,941.80201.400.89%
Nikkei 22548,641.61666.18-1.35%
NZX 50 Index13,377.1070.660.53%
S&P 5006,738.4439.040.58%
S&P/ASX 2009,032.8046.600.52%
SSE Composite Index3,922.418.650.22%

Market Movers